Acute effect of nitric oxide on Raynaud's phenomenon in scleroderma

Lancet

Volumn 354, Issue 9180, 1999, Pages 739-

  Freedman, Robert R ^a   Girgis, Reda ^b   Mayes, Maureen D ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; NITRIC OXIDE; NITROPRUSSIDE SODIUM;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SCLERODERMA;

EID: 0344980419     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)03557-6     Document Type: Article

References (5)

1. Herrick A.L. Advanced in treatment of systemic sclerosis. Lancet. 352:1998;1875.
2. Freedman R.R., Girgis R., Mayes M.D. Adrenergic and endothelial dysfunction in Raynaud's phenomenon and scleroderma. J Rheumatol. 1999;. in press.
3. Kahn R., Coffman J.D. Enhanced cholingeric cutaneous vasodilation in Raynaud's Phenomenon. Circulation. 89:1994;1183-1188.
4. Vallance P., Collier J., Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. ii:1989;997-1000.
5. 1-adrenergic antagonists in idiopathic Raynaud's disease. Circulation. 92:1995;1448-1451.